---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Pharmacokinetics"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Pharmacokinetics. Topics: Clinical half-life as reported in January 2024, Estimated half-life by single-agent dose level as reported in April 2024, Clinical half-life as reported in February 2026, Exposure by dose level, and 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Clinical half-life as reported in January 2024

> “As of December 10, 2023, the initial Phase 1b monotherapy data for ORIC-944”
> “Potential best-in-class drug properties, including clinical half-life consistent with preclinical prediction of >10 hours, which is superior to other PRC2 inhibitors and supports QD dosing”

Source: [ORIC Pharmaceuticals initial phase 1b data release (2024)](https://oricpharma.com/news/oric-pharmaceuticals-provides-initial-phase-1b-data-for-oric-944-operational-highlights-for-2023-and-anticipated-upcoming-milestones/)

<a id="topic-2.1.2.6.3-2"></a>

### Estimated half-life by single-agent dose level as reported in April 2024

| Single-agent dose level | Estimated half-life (hours) |
| --- | --- |
| Dose level 1 | “~17” |
| Dose level 2 | “~19” |
| Dose level 3 | “~18” |
| Dose level 4 | “~26” |
| Dose level 5 | “~20” |

Source: [Friedman (2024)](https://oricpharma.com/wp-content/uploads/2024/04/AACR2024_ORIC-944_NDoH.pdf)

> “Dose level 1 (100mg QD)”
> “Dose level 3 (400mg QD)”
> “Dose level 5 (900mg QD)”
> “Dose exploration continues with favorable plasma half-life of approximately 20 hours”
> “The t1/2 values at Cycle 2 Day 1 were roughly estimated with a terminal phase spanning less than 2 half-lives. Mean half-life is shown for each cohort of patients.”

Source: [Friedman (2024)](https://oricpharma.com/wp-content/uploads/2024/04/AACR2024_ORIC-944_NDoH.pdf)

<a id="topic-2.1.2.6.3-3"></a>

### Clinical half-life as reported in February 2026

> “As of December 10, 2023, these data demonstrated potential best-in-class drug properties, including an approximate 20-hour clinical half-life and no signs of cytochrome P450 autoinduction that is seen with first-generation PRC2 inhibitors.”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="topic-2.1.2.6.3-4"></a>

### Exposure by dose level

> “Increased exposure with dose level”
> “Low peak-to-trough may facilitate better efficacy and safety”

Source: [Friedman (2024)](https://oricpharma.com/wp-content/uploads/2024/04/AACR2024_ORIC-944_NDoH.pdf)

> “Increased exposure with dose, exceeding target Cmin for ~24h”
> “Mean total plasma concentration (nM) at steady state (Cycle 2 Day 1)”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.6.3-5"></a>

### Absence of CYP autoinduction

> “No signs of CYP autoinduction that is seen with first-generation PRC2 inhibitors”

Source: [ORIC Pharmaceuticals initial phase 1b data release (2024)](https://oricpharma.com/news/oric-pharmaceuticals-provides-initial-phase-1b-data-for-oric-944-operational-highlights-for-2023-and-anticipated-upcoming-milestones/)

<a id="topic-2.1.2.6.3-6"></a>

### Food effect with darolutamide

> “Rinzimetostat 400 mg QD plus darolutamide is currently being evaluated in a food effect cohort. Thus far, there does not appear to be a significant food effect, consistent with previous single agent studies.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

> “ORIC is currently evaluating the impact of food for rinzimetostat plus darolutamide on PK, PD, safety and efficacy”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.6.3-7"></a>

### Preclinical solubility, oral bioavailability, and half-life

| Property | Rinzimetostat |
| --- | --- |
| Solubility | “11.7 mg/ml” |
| Mouse oral bioavailability | “64%” |
| Mouse half-life, oral | “3-5 hr PO” |
| Mouse half-life, intravenous | “2.5 hr IV” |
| Clinical half-life | “~20 hrs” |

Source: [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
